



## MedinCell announces the initiation of coverage of its stock by Portzamparc - BNP Paribas Group

Euronext: MEDCL • Montpellier - France • March 27, 2023 – 6:00 pm CEST

- Entitled "*Liberating blockbusters over the long term*", the Portzamparc - BNP Paribas Group report recommends the stock as a buy with a target price of €14.4 per share.
- This new coverage comes as the first product based on MedinCell's long-acting injectable technology is expected to be commercialized in the U.S. in the first half of 2023 (subject to FDA approval); two other products are in Phase 3, with several others in development.
- MedinCell was recently awarded "Prime" status by ISS ESG for its sustainability performance, placing it in the top 10% of companies in the pharmaceutical and biotech industry.
- MedinCell is also covered by Bryan Garnier, Kepler Cheuvreux, ODDO-BHF and TP ICAP.

### About MedinCell

MedinCell is a pharmaceutical technology company that is developing a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed.

U.S. FDA approval for the first product using BEPO® technology for patients with schizophrenia is expected in H1 2023.

Two other products are in clinical Phase 3. In addition, several programs should enter the clinic in 2023 and 2024, including two Global Health initiatives in women's health (contraception) and malaria, supported by the Bill & Melinda Gates Foundation and Unitaid respectively.

Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, and to a reduction in the quantity of medication required. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months, depending on the product, starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.

BEPO® biocompatible polymers, the key components of each MedinCell formulation, are produced and scaled-up at GMP quality level, and already producible at commercial stage through MedinCell's joint-venture with Corbion (Euronext - CRBN).

MedinCell collaborates with tier one pharmaceuticals companies and foundations to improve Global Health through innovative therapeutic options.

Based in Montpellier, MedinCell is a public company (Euronext, MEDCL), currently employing 155 people from over 30 different nationalities.

[www.medincell.com](http://www.medincell.com)

### Contacts

MedinCell

**David Heuzé**

**Head of Communications**

[david.heuze@medincell.com](mailto:david.heuze@medincell.com)

+33 (0)6 83 25 21 86

NewCap

**Louis-Victor Delouvrier / Alban Dufumier**

**Relations investisseurs**

[medincell@newcap.eu](mailto:medincell@newcap.eu)

+33 (0)1 44 71 94 94

NewCap

**Nicolas Merigeau**

**Relations médias**

[medincell@newcap.eu](mailto:medincell@newcap.eu)

+33 (0)1 44 71 94 94